Nivolumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer (NSCLC)
Conditions
Non-Small Cell Lung Cancer (NSCLC), Non-Small-Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms
Trial Timeline
Mar 6, 2018 → Jul 17, 2019
NCT ID
NCT03444766About Nivolumab
Nivolumab is a approved stage product being developed by Bristol Myers Squibb for Non-Small Cell Lung Cancer (NSCLC). The current trial status is completed. This product is registered under clinical trial identifier NCT03444766. Target conditions include Non-Small Cell Lung Cancer (NSCLC), Non-Small-Cell Lung Carcinoma, Nonsmall Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer (NSCLC) were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03126643 | Pre-clinical | Completed |
| NCT02475382 | Pre-clinical | Completed |
| NCT06523621 | Phase 2 | Recruiting |
| NCT06499298 | Pre-clinical | Completed |
| NCT06735781 | Pre-clinical | Completed |
| NCT06421311 | Pre-clinical | Terminated |
| NCT06452329 | Pre-clinical | Completed |
| NCT06003075 | Phase 2 | Terminated |
| NCT06361576 | Pre-clinical | Completed |
| NCT06361563 | Pre-clinical | Completed |
| NCT05068609 | Pre-clinical | Completed |
| NCT04936399 | Pre-clinical | Completed |
| NCT04205409 | Phase 2 | Active |
| NCT04401774 | Phase 2 | Completed |
| NCT04361058 | Phase 1 | Withdrawn |
| NCT04022980 | Phase 1 | Completed |
| NCT04019964 | Phase 2 | Completed |
| NCT04146324 | Pre-clinical | Completed |
| NCT04099251 | Phase 3 | Active |
| NCT03981146 | Phase 2 | Active |
Competing Products
20 competing products in Non-Small Cell Lung Cancer (NSCLC)